These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37852045)

  • 41. Association of
    Du J; Li A; Shi D; Chen X; Wang Q; Liu Z; Sun K; Guo T;
    Neurology; 2023 Jul; 101(1):e40-e49. PubMed ID: 37188537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI).
    Risacher SL; Kim S; Shen L; Nho K; Foroud T; Green RC; Petersen RC; Jack CR; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    Front Aging Neurosci; 2013; 5():11. PubMed ID: 23554593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
    Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
    J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
    Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
    Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
    Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
    Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
    Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer's disease.
    Baek MS; Cho H; Lee HS; Lee JH; Ryu YH; Lyoo CH
    Alzheimers Res Ther; 2020 Oct; 12(1):140. PubMed ID: 33129364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Florbetapir PET-assessed demyelination is associated with faster tau accumulation in an APOE ε4-dependent manner.
    Rubinski A; Dewenter A; Zheng L; Franzmeier N; Stephenson H; Deming Y; Duering M; Gesierich B; Denecke J; Pham AV; Bendlin B; Ewers M;
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1035-1049. PubMed ID: 38049659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study.
    Mattsson N; Ossenkoppele R; Smith R; Strandberg O; Ohlsson T; Jögi J; Palmqvist S; Stomrud E; Hansson O
    Alzheimers Res Ther; 2018 Aug; 10(1):77. PubMed ID: 30086796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors.
    Cooper JG; Ghodsi M; Stukas S; Leach S; Brooks-Wilson A; Wellington CL
    Alzheimers Dement; 2024 Jun; 20(6):4373-4380. PubMed ID: 38752508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
    Nemes S; Logan PE; Manchella MK; Mundada NS; La Joie R; Polsinelli AJ; Hammers DB; Koeppe RA; Foroud TM; Nudelman KN; Eloyan A; Iaccarino L; Dorsant-Ardón V; Taurone A; Thangarajah M; Dage JL; Aisen P; Grinberg LT; Jack CR; Kramer J; Kukull WA; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Vemuri P; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Womack KB; Wolk DA; Rabinovici GD; Carrillo MC; Dickerson BC; Apostolova LG;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S49-S63. PubMed ID: 37496307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
    Öhrfelt A; Benedet AL; Ashton NJ; Kvartsberg H; Vandijck M; Weiner MW; Trojanowski JQ; Shaw LM; Zetterberg H; Blennow K;
    Neurology; 2023 Jan; 100(3):e275-e285. PubMed ID: 36192174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43.
    Wennberg AM; Tosakulwong N; Lesnick TG; Murray ME; Whitwell JL; Liesinger AM; Petrucelli L; Boeve BF; Parisi JE; Knopman DS; Petersen RC; Dickson DW; Josephs KA
    JAMA Neurol; 2018 Nov; 75(11):1347-1354. PubMed ID: 30422173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment.
    Insel PS; Hansson O; Mattsson-Carlgren N
    JAMA Neurol; 2021 Feb; 78(2):229-235. PubMed ID: 33044487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly.
    Slot RER; Kester MI; Van Harten AC; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; van der Flier WM; Veerhuis R
    Neurobiol Aging; 2019 Jul; 79():101-109. PubMed ID: 31029938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.